Core Insights - Amarin Corporation emphasizes the importance of recent innovations in therapies for patients with elevated triglycerides, particularly highlighting the role of VASCEPA/VAZKEPA in expanding treatment options and patient access [1][3][4] Company Overview - Amarin Corporation is focused on advancing cardiovascular therapeutics globally, with VASCEPA/VAZKEPA being a key product that has been prescribed over 25 million times worldwide [1][11] - The company has secured a long-term license and supply agreement with Recordati S.p.A. to commercialize VAZKEPA across 59 countries, enhancing its global reach [6] Product Efficacy - VASCEPA is FDA approved for reducing triglyceride levels in patients with severe hypertriglyceridemia (≥500 mg/dL) and for reducing cardiovascular risks in patients with elevated triglyceride levels [5][14] - The REDUCE-IT trial demonstrated a 25% reduction in cardiovascular events when VASCEPA was used alongside statin therapy in patients with elevated triglyceride levels [5] Market Dynamics - The emergence of new therapies targeting elevated triglycerides is expected to increase the utilization of existing treatments like VASCEPA, as payor-driven step-therapy programs may favor established, cost-effective options [8][9] - Historical data from the launch of PCSK9 inhibitors indicates that similar step-therapy requirements could lead to sustained growth in prescriptions for VASCEPA, as seen with ezetimibe [9] Clinical Significance - Advances in treating severe hypertriglyceridemia and related conditions are crucial for addressing the unmet needs of millions of cardiovascular disease patients globally [4][2] - VASCEPA's unique formulation and proven efficacy position it favorably against other triglyceride-lowering agents that have not demonstrated similar cardiovascular outcomes [5]

Core Insights - Amarin Corporation plc has highlighted a new post hoc analysis from the REDUCE-IT study, demonstrating that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, reinforcing its role in comprehensive cardiovascular risk management [1][3]. Summary by Sections Company Overview - Amarin is a global pharmaceutical company focused on reducing the burden of cardiovascular disease and advancing cardiovascular care, with a commitment to FDA-approved therapies like VASCEPA (icosapent ethyl) [6]. Clinical Findings - The post hoc analysis from the REDUCE-IT study indicates that icosapent ethyl provides cardiovascular protection beyond standard therapies, including statins and aspirin, without additional safety concerns [5]. - Among 8,179 statin-treated participants, 6,179 (75.5%) received aspirin at baseline. Icosapent ethyl reduced major adverse cardiovascular events by 28% in aspirin users, with an absolute risk reduction of 5.9% and a number needed to treat of 17 [4]. - In the subgroup of 4,867 aspirin users, icosapent ethyl reduced total primary endpoint events by 39% [4]. Regulatory Updates - The FDA updated the labeling for fibrates, indicating no cardiovascular benefit when used with statins, emphasizing the need for effective therapies like icosapent ethyl [2]. Market Position - VASCEPA has been prescribed over 25 million times since its launch in the U.S. in January 2020, and it is covered by most major medical insurance plans [7].

Core Insights - Amarin Corporation will present new findings at the American Heart Association's Scientific Sessions 2025, reinforcing the efficacy of VASCEPA®/VAZKEPA® in cardiovascular risk reduction and highlighting the pleiotropic mechanism of action of Eicosapentaenoic Acid (EPA) [1][2] Group 1: Study Findings - New analyses from the REDUCE-IT study will evaluate the clinical benefit of Icosapent Ethyl (IPE) on cardiovascular outcomes with or without baseline use of aspirin [2] - Mechanistic studies will explore the anti-oxidant effects of EPA on lipoprotein(a) [Lp(a)] and its anti-inflammatory and endothelial-protective properties [2] Group 2: Presentation Details - Featured abstracts will be presented by academic collaborators, including a session on the efficacy of Icosapent Ethyl for cardiovascular risk reduction by aspirin use in REDUCE-IT [7] - Additional presentations will cover the effects of EPA on endothelial cells during inflammation and its impact on lipoprotein oxidation [5][8] Group 3: Company Overview - Amarin is a global pharmaceutical company focused on reducing the cardiovascular disease burden and advancing cardiovascular care, with a direct sales approach in the U.S. and an indirect distribution strategy internationally [5] - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising icosapent ethyl, launched in January 2020 for high-risk patients with persistent cardiovascular risk [6][9]